François Ravenelle, PhD, Appointed CEO of Innospera Pharma to Lead Growth Strategy
Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company focused on developing small-molecule modulators of GPR84 and GPR40 to address a broad range of inflammatory and metabolic diseases with high unmet medical needs, on May 6th announced the appointment of François Ravenelle, PhD, as President and Chief Executive Officer, effective immediately. Dr. Ravenelle is an accomplished biotech leader with […]
